Summary
• Tonix Pharmaceuticals (TNXP) shares rose 5.5% in pre-market trading to $17.21 following the launch of Tonmya™, the first FDA-approved treatment for fibromyalgia in over 15 years.
• The company reported $190.1 million in cash and equivalents as of September 30, positioning it to fund operations into Q1 2027; analysts maintain a “Buy” rating on the stock.
• Despite the recent price increase, TNXP’s stock has experienced significant declines, with a yearly performance down 98.8% and year-to-date losses of 99.5%.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has seen a robust pre-market increase of 5.5%, rising to $17.21 from its previous close of $16.31. This upward movement follows the announcement of the commercial availability of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia, marking a significant addition to the market.
Earnings Spark Sharp Move
Tonix’s launch of Tonmya™ is noteworthy as it becomes the first FDA-approved treatment for fibromyalgia in over 15 years. The drug is designed as a non-opioid, once-daily bedtime analgesic that significantly alleviates fibromyalgia pain. Recently, Tonix reported $190.1 million in cash and cash equivalents as of September 30, 2025, a figure that positions the company well to fund operations into the first quarter of 2027.
Analysts currently maintain a “Buy” rating on the stock, reflecting optimism surrounding this significant product launch and the potential market impact of Tonmya™.
Market and Technical Picture
The stock has historically struggled, exhibiting a yearly performance down 98.8% and year-to-date losses of 99.5%. Current metrics reveal the 20-day simple moving average (SMA) at -8.9%, while the 50-day and 200-day SMAs are at -24.4% and -37.8%, respectively. The average volume over the last ten days stands at approximately 754,454 shares, compared to a three-month average of 961,934 shares, indicating relatively low trading activity amidst the stock’s recovery attempt.
Recent SEC Activity
On November 18, Tonix filed an 8-K report updating the market on various disclosures that may impact investor sentiment. The recent filings contain information pertinent to the company’s evolving strategy in the biotechnology space and its operational updates, reinforcing the positive outlook following the product launch.
In summary, shares of Tonix Pharmaceuticals are experiencing notable upward momentum in pre-market trading, largely driven by the promising commercial launch of Tonmya™, reflective of the company’s strategic focus on developing innovative treatments for fibromyalgia.